Development | A Mab A Case Study In Bioprocess
Traditional mAb purification involves a step platform: capture with Protein A, followed by two polishing steps for impurity removal. However, several case studies highlight how this can be optimized or replaced for greater efficiency and lower cost.
Physical, chemical, or biological properties (such as glycosylation patterns or charge variants ) that must stay within a specific range to ensure safety and efficacy.
The top 24 clones were evaluated in automated miniature bioreactors. Clone 14-B7 was selected based on its high specific growth rate ( ) and low lactate accumulation profile. Media and Feed Optimization
The for A Mab included:
Monoclonal antibodies (mAbs) have become the cornerstone of modern biopharmaceuticals, treating everything from oncology and autoimmune disorders to infectious diseases. However, the journey from a hybridoma cell line to a commercially viable product is fraught with complexity. For every successful mAb on the market, there are hundreds of failed attempts—not due to lack of efficacy, but often due to poor bioprocess development.
The structured approach to bioprocess development for mAb-X successfully achieved and exceeded all target parameters within the required timeframe.
The cell line development process involved several rounds of cloning and screening to identify a cell line with the desired characteristics, including: A Mab A Case Study In Bioprocess Development
The N-glycan profiling via hydrophilic interaction liquid chromatography (HILIC) confirmed that the structural integrity of the fragment crystallizable (Fc) region was maintained. This ensured optimal antibody-dependent cellular cytotoxicity (ADCC) effector function. 5. Summary of Results and Key Takeaways
The molecule in this case study is , an IgG1 therapeutic antibody aimed at oncology indications. Target Product Profile (TPP) Indication: Solid tumor oncology. Mechanism of Action: Targeted receptor antagonism.
A-mAb: A Case Study in Bioprocess Development and the Evolution of QbD The top 24 clones were evaluated in automated
A Mab reached the clinic in 28 months from transfection – 6 months ahead of schedule. Today, it’s a blockbuster therapy. But the bioprocess continues to evolve. The team is now implementing (perfused N-1 and connected capture) to boost productivity to 15 g/L and reduce COGS by 40%.
The future of bioprocess development for mAbs is exciting, with several emerging trends and technologies, including: